Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Usana Health Sciences (USNA) EBIT Margin (2016 - 2026)

Usana Health Sciences has reported EBIT Margin over the past 17 years, most recently at 5.54% for Q2 2026.

  • Quarterly EBIT Margin fell 74.0% to 5.54% in Q2 2026 from the year-ago period, while the trailing twelve-month figure was 3.85% through Apr 2026, down 269.0% year-over-year, with the annual reading at 4.05% for FY2026, 372.0% down from the prior year.
  • EBIT Margin was 5.54% for Q2 2026 at Usana Health Sciences, up from 1.69% in the prior quarter.
  • Over five years, EBIT Margin peaked at 12.76% in Q1 2022 and troughed at 0.57% in Q3 2025.
  • The 5-year median for EBIT Margin is 9.04% (2022), against an average of 8.21%.
  • Year-over-year, EBIT Margin skyrocketed 106bps in 2023 and then tumbled -722bps in 2025.
  • A 5-year view of EBIT Margin shows it stood at 9.89% in 2022, then rose by 11bps to 10.95% in 2023, then crashed by -65bps to 3.84% in 2024, then crashed by -85bps to 0.57% in 2025, then surged by 868bps to 5.54% in 2026.
  • Per Business Quant, the three most recent readings for USNA's EBIT Margin are 5.54% (Q2 2026), 1.69% (Q1 2026), and 0.57% (Q3 2025).